Gene is associated with aggressive prostate cancer

December 11, 2007

A variant of a tumor suppressor gene may be associated with an increased risk of aggressive prostate cancer, according to a study published online December 11 in the Journal of the National Cancer Institute.

Consistent findings that prostate cancer has a genetic component have led researchers to suspect that there are genetic variants that predispose some men to develop prostate cancer.

Jianfeng Xu, M.D., Ph.D., of Wake Forest University School of Medicine in Winston-Salem, N.C., and colleagues examined whether genetic changes to single DNA base-pairs, known as SNPs (single nucleotide polymorphisms), are associated with aggressive prostate cancer in a population of nearly 1,000 Swedish men with and without the disease. The SNPs that were most strongly associated with aggressive prostate cancer were further tested in two independent groups of men who were treated or screened for prostate cancer at Johns Hopkins Hospital in Baltimore.

Starting with about 60,000 SNPs, the researchers conducted an exploratory analysis that identified seven SNPs associated with aggressive prostate cancer. After further testing in the Johns Hopkins population, the authors confirmed that one SNP located in the DAB2IP gene, which is known to be a tumor suppressor gene, was associated with aggressive prostate cancer among men of European and African American descent.

"Our study is among the first to report the presence of a potentially important prostate cancer aggressiveness locus...However, we cannot rule out the possibility of false-positive association. This report is intended to stimulate the conduct of additional confirmation studies for a gene that has strong initial statistical support and biologic relevance as a tumor suppressor gene," the authors write.

In an accompanying editorial, Jer-Tsong Hsieh, Ph.D., of the University of Texas Southwestern Medical Center in Dallas and colleagues, who first identified this gene, discuss their studies that suggest the DAB2IP gene plays a role in the progression of prostate cancer.

"Several other findings support the biologic role of this gene in aggressive prostate cancer," the editorialists write.
-end-
Contact: Citations: Note to Reporters:

We have started up an e-mail list to alert reporters when papers are available on the EurekAlert site. If you would be interested on being on this list, please let us know at jncimedia@oxfordjournals.org. The content will continue to be available through EurekAlert's e-mail system and our EurekAlert page.

The Journal of the National Cancer Institute is published by Oxford University Press and is not affiliated with the National Cancer Institute. Attribution to the Journal of the National Cancer Institute is requested in all news coverage. Visit the Journal online at http://jnci.oxfordjournals.org/.

Journal of the National Cancer Institute

Related Prostate Cancer Articles from Brightsurf:

Low risk of cancer spread on active surveillance for early prostate cancer
Men undergoing active surveillance for prostate cancer have very low rates - one percent or less - of cancer spread (metastases) or death from prostate cancer, according to a recent study published in the Journal of Urology®, an Official Journal of the American Urological Association (AUA).

ESMO 2020: Breast cancer drug set to transform prostate cancer treatment
A drug used to treat breast and ovarian cancer can extend the lives of some men with prostate cancer and should become a new standard treatment for the disease, concludes a major trial which is set to change clinical practice.

Major trial shows breast cancer drug can hit prostate cancer Achilles heel
A drug already licensed for the treatment of breast and ovarian cancers is more effective than targeted hormone therapy at keeping cancer in check in some men with advanced prostate cancer, a major clinical trial reports.

The Lancet: Prostate cancer study finds molecular imaging could transform management of patients with aggressive cancer
Results from a randomised controlled trial involving 300 prostate cancer patients find that a molecular imaging technique is more accurate than conventional medical imaging and recommends the scans be introduced into routine clinical practice.

Common genetic defect in prostate cancer inspires path to new anti-cancer drugs
Researchers found that, in prostate cancer, a mutation leading to the loss of one allele of a tumor suppressor gene known as PPP2R2A is enough to worsen a tumor caused by other mutations.

First prostate cancer therapy to target genes delays cancer progression
For the first time, prostate cancer has been treated based on the genetic makeup of the cancer, resulting in delayed disease progression, delayed time to pain progression, and potentially extending lives in patients with advanced, metastatic prostate cancer, reports a large phase 3 trial.

Men taking medications for enlarged prostate face delays in prostate cancer diagnosis
University of California San Diego School of Medicine researchers report that men treated with medications for benign prostatic hyperplasia (enlarged prostate) experienced a two-year delay in diagnosis of their prostate cancer and were twice as likely to have advanced disease upon diagnosis.

CNIO researchers confirm links between aggressive prostate cancer and hereditary breast cancer
The study has potential implications for families with members suffering from these types of tumours who are at an increased risk of developing cancer.

Distinguishing fatal prostate cancer from 'manageable' cancer now possible
Scientists at the University of York have found a way of distinguishing between fatal prostate cancer and manageable cancer, which could reduce unnecessary surgeries and radiotherapy.

Researchers find prostate cancer drug byproduct can fuel cancer cells
A genetic anomaly in certain men with prostate cancer may impact their response to common drugs used to treat the disease, according to new research at Cleveland Clinic.

Read More: Prostate Cancer News and Prostate Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.